Compositions comprising immunoreactive reagents and saponins, and methods of use thereof

a technology of immunoreactive reagents and saponins, which is applied in the field of pharmaceutical compositions, can solve the problems of not being desirable for use in veterinary practice or in pharmaceutical compositions for man, still exhibiting considerable heterogeneity, and not all of these saponins were active as adjuvants, and achieve the effect of enhancing the immune respons

Inactive Publication Date: 2006-09-21
CSL LTD
View PDF24 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The first commercially available Quillaja saponin adjuvants were crude extracts which, because of their variability, were not desirable for use in veterinary practice or in pharmaceutical compositions for man.
However, while Dalsgaard's preparation, “Quil-A,” was a definite improvement over the previously available commercial saponins, it still exhibited considerable heterogeneity.
However, not all of these saponins were active as adjuvants.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response, and methods of formulating the compositions. In certain embodiments, the outcome of eliciting an immune response is prophylaxis or therapy. The compositions of the invention can be used to provide improved passive immunotherapy against cancer or an agent of infectious disease or neurodegenerative / amyloid diseases or any other disease or pathological state that can be treated by passive immunotherapy, by administering to an individual a therapeutic amount of the immunoreactive reagent and saponin.

[0024] Cancers that can be treated according to the methods of the invention include, but are not limited to, leukemia (e.g., acute leukemia such a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
dry weightaaaaaaaaaa
pHaaaaaaaaaa
Login to view more

Abstract

The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response, and methods of formulating the compositions. The compositions comprise an immunoreactive reagent (i.e., an antigen binding protein comprising an antigen binding region and a region or regions of an antibody that mediate antibody dependent immunological processes) and a saponin. The present invention also relates to methods of using the compositions of the invention for the prevention and / or treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response.

Description

1. FIELD OF THE INVENTION [0001] The present invention relates to pharmaceutical compositions that are useful for the prevention and treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid diseases, or any other disease wherein the treatment of such disease would be improved by an enhanced immune response, and methods of formulating the compositions. The compositions comprise an immunoreactive reagent (i.e., an antigen binding protein comprising an antigen binding region and a region or regions of an antibody that mediate antibody dependent immunological processes) and a saponin. Such antibody dependent processes include, but are not limited to, antibody dependent cellular cytotoxicity and phagocytosis. The present invention also relates to methods of using the compositions of the invention for the treatment of infectious diseases, primary and metastatic neoplastic diseases (i.e., cancer), neurodegenerative or amyloid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K31/704A61K39/39
CPCA61K31/704A61K39/395A61K39/39558A61K45/06A61K2039/55577A61K2300/00A61P25/00A61P25/28A61P31/00A61P31/04A61P31/10A61P31/12A61P33/00A61P35/00A61P37/04Y02A50/30
Inventor KENSIL, CHARLOTTEA
Owner CSL LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap